Intravitreal Lower- Dose (20 mu g) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds

Date
2015
Author
Balci, Ozlem
Kebudi, Rejin
Tuncer, Samuray
Tanyildiz, Burak
Shields, Carol L.
Metadata
Show full item record
Abstract
BACKGROUND AND OBJECTIVE: The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 mu g) intravitreal melphalan for VS.
URI
http://hdl.handle.net/20.500.12627/12999
https://doi.org/10.3928/23258160-20151008-07
Collections